Covered recipient · General Payments record
JACKLYN MICHELLE PLATT
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2022–2023
$577.60
- Reported across 35 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $297.00 | 16 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $152.47 | 7 |
| Acerta Pharma LLC | $32.49 | 2 |
| Novo Nordisk AS | $31.15 | 2 |
| Lilly USA, LLC | $30.24 | 2 |
| Corcept Therapeutics | $21.85 | 1 |
| Janssen Pharmaceuticals, Inc | $15.16 | 1 |
| Exact Sciences Corporation | $13.64 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.44 | 04/24/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1009269933 | CMS |
| ABBVIE INC. | $14.96 | 05/08/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1009269939 | CMS |
| ABBVIE INC. | $17.08 | 05/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1009269948 | CMS |
| ABBVIE INC. | $19.56 | 05/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1009269957 | CMS |
| ABBVIE INC. | $28.78 | 06/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1009269965 | CMS |
| ABBVIE INC. | $18.67 | 08/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1009269971 | CMS |
| ABBVIE INC. | $33.98 | 10/05/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1009269981 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.89 | 05/04/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1015958593 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.60 | 08/23/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1011535829 | CMS |
| Corcept Therapeutics | $21.85 | 09/21/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1050841287 | CMS |
| Exact Sciences Corporation | $13.64 | 07/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1026841297 | CMS |
| Janssen Pharmaceuticals, Inc | $15.16 | 01/13/2023 | Food and Beverage | Undisputed | 01/23/2026 | 988103553 | CMS |
| Lilly USA, LLC | $13.63 | 02/21/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1032947947 | CMS |
| Lilly USA, LLC | $16.61 | 06/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1032813483 | CMS |
| Novo Nordisk Inc | $14.70 | 04/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1002320369 | CMS |
| Novo Nordisk Inc | $16.45 | 07/19/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1002320379 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023
- Source files
- Dataset page · Bulk file · PY2022 , PY2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.